Literature DB >> 27461656

Flavopiridol's antiproliferative effects in glioblastoma multiforme.

Gozde Cobanoglu1, Irem Dogan Turacli2, Ayla Cihan Ozkan1, Abdullah Ekmekci1.   

Abstract

AIM OF STUDY: Glioblastoma multiforme (GBM) is largely refractory to surgical operation, radiotherapy, and chemotherapy in use today. Remaining lifetime accounting for the GBM-affected patients varies between 12 and 16 months generally. The most frequently altered genes in GBM are p53, epidermal growth factor receptor, PTEN, and cyclin-dependent kinase inhibitor 2A. Our aim is to investigate the antiproliferative and apoptotic effects of flavopiridol, a cyclin-dependent kinases and specific phosphokinase inhibitor, on glioblastoma cell lines having different genetic profiles: U87MG, U118MG, and T98G.
MATERIALS AND METHODS: Cell viability and IC50 values were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, protein expressions were determined by Western blot and caspase activities were analyzed by activity kit.
RESULTS: Western blot analysis showed down-regulation of the cyclin D1, c-Myc, and p53 protein activities, and up-regulation of p27KIP1 activity after flavopiridol treatment. Additionally, flavopiridol diminished p-Akt protein levels generally which induces inhibition of proliferation.
CONCLUSION: The present study demonstrated that flavopiridol did not induce caspase-3/7 activation, BIM, and BAX pro-apoptotic proteins but it leads to the expression changes of various proteins that inhibit proliferation and eternity in glioblastoma cell lines which have different genetic alterations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27461656     DOI: 10.4103/0973-1482.172132

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  7 in total

Review 1.  Involvement of Phytochemical-Encapsulated Nanoparticles' Interaction with Cellular Signalling in the Amelioration of Benign and Malignant Brain Tumours.

Authors:  Sidharth Mehan; Navneet Arora; Sonalika Bhalla; Andleeb Khan; Muneeb U Rehman; Badrah S Alghamdi; Torki Al Zughaibi; Ghulam Md Ashraf
Journal:  Molecules       Date:  2022-06-01       Impact factor: 4.927

Review 2.  Centrosome - a promising anti-cancer target.

Authors:  Yainyrette Rivera-Rivera; Harold I Saavedra
Journal:  Biologics       Date:  2016-12-13

3.  Discovering mutated driver genes through a robust and sparse co-regularized matrix factorization framework with prior information from mRNA expression patterns and interaction network.

Authors:  Jianing Xi; Minghui Wang; Ao Li
Journal:  BMC Bioinformatics       Date:  2018-06-05       Impact factor: 3.169

4.  Overexpression of CLEC18B Associates With the Proliferation, Migration, and Prognosis of Glioblastoma.

Authors:  Rui-Ming Guo; Cheng-Bin Zhao; Peng Li; Liang Zhang; Su-Hua Zang; Bo Yang
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

Review 5.  Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions.

Authors:  Viktorija Juric; Brona Murphy
Journal:  Cancer Drug Resist       Date:  2020-03-19

Review 6.  Drug Repositioning in Glioblastoma: A Pathway Perspective.

Authors:  Sze Kiat Tan; Anna Jermakowicz; Adnan K Mookhtiar; Charles B Nemeroff; Stephan C Schürer; Nagi G Ayad
Journal:  Front Pharmacol       Date:  2018-03-16       Impact factor: 5.810

7.  New cytotoxic compounds from the leaves of Caesalpinia benthamiana (Baill.) Herend. & Zarucchi (Fabaceae).

Authors:  Tayo I Famojuro; Taiwo O Elufioye; Olumayokun A Olajide; Michael Dybek; Adeboye Adejare
Journal:  Avicenna J Phytomed       Date:  2021 Jan-Feb
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.